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Glomerulosclerosis, interstitial fibrosis, and tubular atrophy
occur with end-stage kidney failure, irrespective of the
primary etiology. The transforming growth factor-b (TGF-b) is
a key factor in these alterations either directly, by stimulating
synthesis of extracellular matrix components and reducing
collagenase production, or indirectly through other
profibrogenic factors such as connective tissue growth factor
(CTGF). TGF-b is important for the proliferation of intrarenal
fibroblasts and the epithelial–mesenchymal transition
through which tubular cells become fibroblasts. Although
several factors induce TGF-b expression in the kidney,
one very interesting aspect is the link between the
renin–angiotensin—aldosterone (Aldo) system (RAAS) and
TGF-b. Angiotensin II (ANG II) stimulates TGF-b expression in
the kidney by various mechanisms and upregulates receptors
for TGF-b. ANG II can directly phosphorylate Smads without
inducing TGF-b. Recent data provide compelling evidence
that other components of the RAAS including ANG III,
renin, and Aldo also activate the TGF-b system. As direct
modulation of the TGF-b system is not yet feasible in
humans, angiotensin-converting enzyme (ACE) inhibitors and
angiotensin type 1 (AT1)-receptor blockers are currently the
most potential drugs to interfere with this ANG II-mediated
TGF-b expression. This review highlights some current
aspects of the interaction between the RAAS and the
TGF-b axis.
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Many chronic renal diseases, irrespective of the primary
etiology, progress to end-stage renal disease with an
irreversible loss of renal tissue.1 Glomerulosclerosis, fibrosis
of the tubulointerstitial microenvironment, and tubular
atrophy all constitute the major morphological correlates of
such end-stage kidneys. Deposition of extracellular matrix
proteins including fibronectin, collagen types I, III, and IV is
an important component of the scarring observed during the
evolution of glomerulosclerosis and tubulointerstitial fibro-
sis.1 An increase in the synthesis as well as a decrease in
turnover of these proteins is, as a simplification, responsible
for the net accumulation of extracellular matrix. Transform-
ing growth factor-b (TGF-b) serves as a paradigm for a
profibrogenic cytokine.2,3 Its function in the renal patho-
physiological process has been investigated in landmark
studies by Border et al.2 TGF-b directly stimulates transcrip-
tion of many extracellular matrix genes in renal cells
including mesangial, endothelial, and tubular cells.3 During
renal fibrosis new fibroblasts are derived mainly through
epithelial–mesenchymal transition, a process principally
driven by TGF-b.4 On the other hand, TGF-b reduces
collagenase production and simultaneously stimulates ex-
pression of tissue inhibitor of metalloproteinases, resulting in
an overall inhibition of extracellular matrix turnover.5
Members of the TGF-b family interact with specific receptors
resulting in the activation of distinct signal-transduction
pathways, mainly involving Smad proteins.6,7 Some of the
profibrotic effects of TGF-b are actually mediated by the
connective tissue growth factor (CTGF), a member of the
CCN (cyr61, ctgf, nor) family of early response genes.8 For
example, CTGF stimulates proliferation of renal fibroblasts
and induces extracellular matrix synthesis.
An early feature of chronic renal disease, before glomerulo-
sclerosis and tubulointerstitial fibrosis have yet developed, is
the recruitment of macrophages/monocytes from the circula-
tion into the local tissue.9 It has been reported that TGF-b
functions as a chemoattractant for macrophages/monocytes
and regulates the survival of lymphocytes, natural killer cells,
and dendritic cells.9 On the other hand, TGF-b can also exert
anti-inflammatory properties as shown in atherosclerosis.10
Compensatory growth processes, such as hypertrophy and/or
hyperplasia, are characteristic findings of chronic kidney
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disease as nephrons surviving the injury may undergo
adaptive growth to compensate for the loss of functional
renal tissue.11 Cell culture studies have revealed that TGF-b
arrests renal cells in the G1 phase of the cell cycle, and
stimulates cellular hypertrophy by a variety of mechanisms
including inhibition of cyclin-dependent kinases by induc-
tion of cyclin-dependent kinase inhibitors such as p27Kip1
and p21.12 It has also been demonstrated that TGF-b may
exert proliferative actions on renal cells under specific
conditions.13
TGF-b additionally exerts hemodynamic effects. It impairs
renal autoregulation via the generation of reactive oxygen
species.14 Recent evidence shows that Emilin1 (an inhibitor of
active TGF-b formation) knockout mice have increased blood
pressure, increased peripheral vasculature resistance, and
reduced vessel size indicating a potential role of TGF-b in
hypertension.15 Interestingly, TGF-b stimulates angiotensino-
gen gene expression, at least in proximal tubular cells,
indicating a positive feedback loop that further enhances renal
injury.16 Thus, activation of the TGF-b axis explains many
morphological alterations of chronically failing kidneys.
The landmark studies by Anderson et al.17 showing the
superiority of angiotensin-converting enzyme (ACE) inhibi-
tors in halting the progression of renal disease, suggest that
angiotensin II (ANG II) plays a pivotal role in the
pathophysiology of chronic renal disease.18 There is now
ample evidence that activation of the renin–angiotensin—
aldosterone (Aldo) system (RAAS) is a key mediator in the
progression of renal disease. There is a close interaction
between the RAAS and the TGF-b systems.19–22 In fact, many
profibrotic effects of ANG II are mediated by stimulation of
TGF-b. The current review describes more recent insights
into the link between the RAAS and the TGF-b axis.
ANG II-MEDIATED STIMULATION OF THE TGF-b AXIS
TGF-b1 is the prototype of a family of more then 35
structurally related cytokines. This family also includes TGF-
b2, TGF-b3, activins, and bone morphogenetic proteins.
Although these other members, particularly bone morpho-
genetic protein-7 as an antifibrotic agent, are of considerable
interest, they will not be further discussed here and the reader
is referred to excellent editorials23,24 The synthesis of TGF-b
is a complex process. The translated protein is a TGF-b
precursor termed preproTGF-b, which contains a signal
peptide. Pro-TGF-b is processed in the Golgi apparatus by a
furin-like protease. A homodimer of this new protein, the
latency-associated protein, is noncovalently bound to the
homodimer of the mature TGF-b. The latency-associated
protein/TGF-b complex can be secreted as such or can
associate with the latent TGF-b-binding protein. In order
to bind to its putative receptors, TGF-b must be liberated
from latency-associated protein. Several mechanisms have
been found to lead to the release of TGF-b. For example,
thrombospondin, through the physical interaction with
latency-associated protein, releases free TGF-b. Principally,
components of the RAAS can upregulate TGF-b concentra-
tion by influencing several of the mechanisms described
above.
Early evidence that ANG II stimulates TGF-b messenger
RNA (mRNA) expression stems from observations of
cultured vascular smooth muscle cells.25 Moreover, in
cultured vascular smooth muscle cells, ANG II not only
stimulated transcription of TGF-b, but also promoted its
conversion to the biologically active form.26 Our group was
the first to demonstrate that ANG II stimulates TGF-b
synthesis in renal cells.27 We had previously noticed that
ANG II decreased proliferation, but induced cellular
hypertrophy of cultured proximal tubular cells.28 This
enlargement of tubular cells in the presence of ANG II was
associated with stimulated transcription and synthesis of
collagen type IV, but not of type I.6 Application of exogenous
TGF-b mimicked the growth effects observed with ANG II in
proximal tubular cells (inhibition of DNA synthesis and
stimulation of hypertrophy).27 Cells stimulated with ANG II
expressed more TGF-b1 mRNA and produced bioactive TGF-
b.27 These effects were transduced through angiotensin type 1
(AT1) receptors. Moreover, neutralizing anti-TGF-b antibody,
but not control immunoglobulin G, abolished the ANG II-
mediated inhibition of proliferation as well as the induction
of cellular hypertrophy indicating that part of ANG II-
induced growth effects were in fact mediated by TGF-b.27 In
a subsequent study, we provided evidence that ANG II
directly stimulates transcription of the TGF-b1 gene.
29 The
murine as well as the human TGF-b1 promoter contain two
putative transcriptional start sites, with several sequence
specific transcription factor 1-binding and activator protein
(AP)-2-like sequences and AP-1 binding motifs located in the
50end. Transient transfection of different chimeric constructs
into proximal tubular cells revealed that ANG II stimulates
TGF-b1 transcription from both start sites.
29 As ANG II
induces c-fos and c-jun, and the protein products of these two
immediate early genes form a leucine zipper which can bind
to AP-1 sites, it is likely that the ANG II-stimulated
transcription of TGF-b1 is mediated through these AP-1
sites. Subsequent studies have confirmed that ANG II,
through protein kinase C and p38 mitogen-activated protein
kinase-dependent pathways, activate the binding of nuclear
proteins to the AP-1-box B of the TGF-b1 promoter and
stimulate transcriptional activity.30
In addition to direct stimulation of TGF-b1 transcription,
ANG II also enhances the concentration of the TGF-b1
protein by additional mechanisms. ANG II stimulates
through the p38-mitogen-activated protein kinase and
c-jun N-terminal kinase signaling thrombospondin-1 that,
in turn, leads to an increased release of active TGF-b1 from
the inactive latent complex.31,32 Thus, ANG II-dependent
transcriptional and post-transcriptional mechanisms enhance
TGF-b expression. ANG II-mediated TGF-b induction in the
kidney is not restricted to the proximal tubule. It has been
described that ANG II treatment of rat mesangial cells in
culture increases TGF-b as well as the matrix components
biglycan, fibronectin, and collagen type I.33
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TGF-b mediates its biological functions through binding
to type I and II receptors. Endoglin is a glycoprotein that
functions as a type III receptor for TGF-b. Interestingly, TGF-
b2 is only able to signal in the presence of the type III
receptor whereas TGF-b1 and TGF-b3 do not require
endoglin as receptor for activation of downstream signaling.
Endoglin cannot bind TGF-b in the absence of type II
receptors, but may modulate signal transduction of type I
and II heterodimers. The active form of TGF-b1 initially
engages the TGF-b receptor type II. In a second step this
brings the type II receptor in proximity and then activates the
type I receptor, which phosphorylates intracellular Smad
proteins. Eight Smad proteins have been identified and are
grouped into three categories (receptor-associated Smads: 1,
2 3, 5, and 8); one common Smad (Smad 4), and two
inhibitory Smads (6 and 7). Some Smads such as 1, 5, and 8
are exclusively involved in signaling of other ligands of the
TGF-b superfamily.34 The common Smad 4 forms hetero-
meric complexes with receptor-associated Smads. The com-
plexes then translocate to the nucleus and modulate gene
expression.34 There is also evidence of Smad-independent
TGF-b signaling pathways.35
We have shown in proximal tubular cells that ANG II
stimulated protein expression of TGF-b receptor type II, but
not that of type I.36 This stimulated receptor expression was
reflected in an overall increase of specific binding of TGF-b1
to cells.36 Moreover, ANG II increased mRNA expression for
TGF-b receptor type II. Reporter gene experiments indicated
that AP-1 sites in the promoter for TGF-b receptor type II are
a necessary prerequisite for ANG II-induced transcriptional
activity.36 In a culture system, albumin (as a factor
mimicking proteinuria) leads to upregulation of type II
TGF-b receptors via stimulation of ANG II.37 This can
amplify profibrogenic actions of TGF-b suggesting a
mechanism for how proteinuria leads to tubulointerstitial
fibrosis. ANG II increased the expression of endoglin mRNA
and protein in cardiac fibroblasts without effects on type I
and II TGF-b receptors.38 As endoglin is essential for the
binding of TGF-b2, this effect would presumably stimulate
TGF-b2 signaling. Rodriguez-Vita et al.39 as well as Wang
et al.40 have shown new twists in how ANG II can stimulate
the TGF-b axis. These investigators discovered that ANG II
phosphorylates Smad 2 and 3 independently of TGF-b. The
effects were transduced by AT1 receptors, and dependent on
extracellular signal-regulated kinase (Erk) 1, 2, and p38
mitogen-activated protein kinase signal transduction. These
fascinating data suggest that Smad pathways are not
exclusively activated by the classic TGF-b-triggered mechan-
isms, and that profibrogenic pathways can be activated by
ANG II without directly stimulating TGF-b.39,40
ANG II also induces other profibrotic factors. CTGF, a
downstream key mediator of TGF-b’s profibrogenic effects, is
directly and independently of TGF-b, induced by ANG II via
a calcineurin-associated pathway.41–43 In addition, Iwanciw
et al.44 found that ANG II-mediated CTGF expression
requires Erk 1,2, and Rho signaling. In podocytes, ANG II
stimulates the expression of the vascular endothelial growth
factor.45 Vascular endothelial growth factor, in turn, leads to
an upregulation of the TGF-b receptor type II and increased
Smad2 phosphorylation.46 As a consequence, a3(IV) collagen
protein synthesis is stimulated in podocytes,45 an effect that
presumably contributes to the thickening of the glomerular
basement membrane in pathophysiological conditions such
as diabetic nephropathy.
ACTIVATION OF THE TGF-b AXIS BY OTHER RAAS
COMPONENTS
ANG III, through binding to AT1 receptors, increases TGF-b1
mRNA expression in mesangial cells and in renal interstitial
fibroblasts.47 This peptide also increases extracellular matrix
synthesis in these cells in a TGF-b-dependent manner.47 ANG
IV does not directly stimulate TGF-b expression, but
influences extracellular matrix turnover by increasing ex-
pression of the plasminogen activator inhibitor-1, a potent
inhibitor of metalloproteinases that are involved in extra-
cellular matrix degradation.48 Although Aldo is profibrotic
through induction of plasminogen activator inhibitor-1,49 it
has been found to additionally induce TGF-b protein by a
post-transcriptional mechanism without influencing TGF-b
transcripts.50 Moreover, Aldo promotes ANG II-mediated
signal-transduction effects such as Erk 1,2, and c-Jun
N-terminal kinase phosphorylation.51 As TGF-b has been
shown to activate Erk 1,2 through Smad-independent
pathways,35 Aldo and TGF-b may act synergistically in
stimulating downstream signaling events. Fascinating
recent evidence suggests that renin increases mesangial cell
TGF-b expression and matrix proteins through a specific
receptor, independent of ANG II.52 Specific receptors for
renin have been characterized on mesangial cells and
vascular smooth muscle cells that provoke a rapid acti-
vation of Erk 1,2.53 Remarkably, renin-stimulated TGF-b
expression was independent of its proteolytic activity.52 These
findings suggest that renin can contribute to TGF-b
expression and renal fibrosis through two different mechan-
isms: directly, by binding to specific receptors and indirectly,
via the generation of ANG II and subsequent TGF-b
induction.54
CLINICAL EVIDENCE OF RAAS-MEDIATED STIMULATION
OF TGF-b AXIS
The role of ANG II and other RAAS components in the
activation of the TGF-b axis has also been found in animal
models ranging from reduction of renal mass, Marfan
syndrome, renal artery stenosis to calcineurin-inhibitor
toxicity.55–58 One of the first models in which the link
between the RAAS and TGF-b was comprehensively studied
was unilateral ureteral ligation.59 In this model, TGF-b1
mRNA levels are increased in the obstructed kidney 3 days
after surgery, but do not change significantly in the
contralateral kidney.59 Treatment with the ACE inhibitor
enalapril significantly blunted this increase in TGF-b1
mRNA.59,60 Moreover, an AT1-receptor antagonist was
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equally effective in halting the increase of TGF-b1 mRNA in
the obstructed kidney.61
Naturally, the clinical evidence is more indirect and stems
mainly from measuring urinary TGF-b excretion that is
thought to be mainly derived from the kidney under RAAS
blockade in various diseases.62–75 Table 1 gives an overview
of some of the published studies. The data indicate that
ACE inhibitor as well as AT1-receptor antagonists reduce
urinary TGF-b protein levels. Biopsy studies in patients
with membranous nephropathy also reveal that renal
in situ formation of ANG II could participate in TGF-b
upregulation.76
CONCLUSION
Convincing and accumulating evidence increasingly indicates
that ANG II and other members of the RAAS activate the
TGF-b axis in the kidney by both direct and indirect
mechanisms (Figure 1). As renal TGF-b is a key player in the
development of morphological changes such as glomerulo-
sclerosis and tubulointerstitial fibrosis, strategies to hinder
this profibrogenic cytokine are essential to prevent the loss of
functioning renal tissue. Despite the fact that a wide array of
new approaches to interfere with TGF-b expression has been
tested including application of neutralizing antibodies,
antisense oligonucleotides, overexpression of decorin, and
tranilast, these treatments are not easily adaptable to humans.
However, ACE inhibitors and AT1-receptor blocker are drugs
that interfere with TGF-b expression and should be part of
every regimen to halt progression of renal disease. As RAAS
can activate the TGF-b axis by several mechanisms, a more
complete blockade would presumably also reduce the
deleterious effects of TGF-b on the kidney.77
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